Acumen Pharmaceuticals, Inc.
Company Stats
- Market Cap
- $160.5M
- as of Sep 30, 2026
- Enterprise Value
- $137.7M
- Shares Outstanding
- 72.3M
- Free Float
- 54.5%
Income Statement
- Operating Income
- -$123.8M
- Net Income
- -$121.3M
- EBITDA
- -$123.8M
Cash Flow
- Free Cash Flow
- -$115.6M
- FCF Yield
- -72.0%
- Owner FCF Yield
- -78.2%
Balance Sheet
- Cash & Equivalents
- $54.0M
- Total Debt
- $31.2M
- Net Cash
- $22.8M
Returns & Capital
- SBC, 3Y Avg
- $8.5M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | — | -$115.6M | — |
| FY2024 | — | -$86.2M | — |
| FY2023 | — | -$43.1M | — |
| FY2022 | — | -$35.3M | — |
| FY2021 | — | -$18.0M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of October 31, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges